Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on January 6, 2023, covering events occurring on January 4, 2023. The filing primarily addresses the results of a Special Meeting of Stockholders held to approve a reverse stock split.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions rather than financial performance data.
Material Changes and Corporate Actions
- Reverse Stock Split Approval: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-25. The exact ratio and effective date are to be determined by the Board of Directors.
- Voting Results:
- For: 19,728,800 votes
- Against: 4,120,599 votes
- Abstain: 150,982 votes
- Shareholder Composition: As of the record date (November 17, 2022), there were 13,667,973 shares of common stock and one share of Series D preferred stock outstanding. The preferred stock holder held 17,500,000 votes, which were automatically voted in proportion to the common stock votes.
Guidance, Outlook, and Disclosures
- Investor Presentation: On January 6, 2023, the Company posted an updated investor presentation and webcast on its website (www.phiopharma.com), included as Exhibit 99.1.
- Regulation FD: The information in the investor presentation is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Future Reporting: The specific ratio and effective date of the reverse stock split will be reported in a separate Form 8-K once approved by the Board.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and effective date in the subsequent Form 8-K filing.
- Review the attached Investor Presentation (Exhibit 99.1) for updated business strategy and financial outlook not detailed in this text.
- Monitor the Company's compliance with NASDAQ Capital Market listing standards following the stock split.
- Confirm the impact of the reverse stock split on the number of outstanding shares and share price.